Nick Abbott
Stock Analyst at Wells Fargo
(0.10)
# 4,391
Out of 5,022 analysts
5
Total ratings
25%
Success rate
-33.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nick Abbott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Overweight | $45 → $9 | $18.23 | -50.63% | 1 | Oct 4, 2022 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $450 | $3.44 | +12,981.40% | 2 | Oct 4, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $7 → $1.5 | $0.16 | +837.50% | 1 | Oct 4, 2022 | |
| CLLS Cellectis | Downgrades: Equal-Weight | $16 | $4.17 | +283.69% | 1 | Jan 6, 2022 |
Zymeworks
Oct 4, 2022
Assumes: Overweight
Price Target: $45 → $9
Current: $18.23
Upside: -50.63%
Alaunos Therapeutics
Oct 4, 2022
Assumes: Overweight
Price Target: $450
Current: $3.44
Upside: +12,981.40%
Adaptimmune Therapeutics
Oct 4, 2022
Maintains: Equal-Weight
Price Target: $7 → $1.5
Current: $0.16
Upside: +837.50%
Cellectis
Jan 6, 2022
Downgrades: Equal-Weight
Price Target: $16
Current: $4.17
Upside: +283.69%